Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab emtansine in HER2-positive advanced solid tumors
NL-OMON46221Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in bladder cancer, pancreatic cancer (PC) and cholangiocarcinoma (CCA), sponsored by Roche. Primary endpoint: Best overall response rate. Started Mar 2017; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
bladder cancerpancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NL-OMON46221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46221.